FDA’s Overcaution Carries Deadly Consequences

December 10, 2018

When the FDA sets out to evaluate a potential new drug, the agency’s overcaution makes the exercise more expensive and potentially deadly from patients who might benefit. Mark Flatten of the Goldwater Institute comments.

Download:mp3


Subscribe to Cato Daily Podcast:

Listen on Apple Podcasts Get it on Google Play Subscribe via RSS Listen on Spotify 

Recent Cato Daily Podcast